Literature DB >> 26250749

Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease.

Daniel Jahn1, Monika Rau1, Heike M Hermanns1, Andreas Geier2.   

Abstract

The gut-derived hormone fibroblast growth factor 15/19 (FGF15/19) is an emerging versatile regulator of various metabolic pathways. As such, FGF15/19 has been implicated in homeostatic control of bile acid, carbohydrate and lipid metabolism in multiple target organs including the liver, adipose tissue and brain. In line with this, growing evidence suggests that dysregulation of FGF15/19 contributes to a number of metabolic and bile acid-associated disorders such as fatty liver disease, Type 2 diabetes and different gastrointestinal dysfunctions. In this review we summarize the current knowledge on the organ-specific functions of FGF15/19 and address their underlying molecular mechanisms. Moreover, recent advances in the characterization of factors that control the release of the hormone in the gut will be discussed and linked to the current view of how alterations of FGF15/19 signaling may contribute to disease development. Finally, the suitability of FGF15/19 as a potential therapeutic target will be critically reviewed.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bile acid signaling; Energy metabolism; Fibroblast growth factor 15/19; Liver disease; Nuclear receptors; Obesity

Mesh:

Substances:

Year:  2015        PMID: 26250749     DOI: 10.1016/j.cytogfr.2015.07.016

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  20 in total

1.  What if Prometheus had steatosis? Potential use of FGF19 to promote regeneration of the fatty liver.

Authors:  Philip M Brown; Yaron Rotman
Journal:  Gut       Date:  2017-03-08       Impact factor: 23.059

Review 2.  Fibroblast growth factors 19 and 21 in acute liver damage.

Authors:  Zhao Shan; Gloria Alvarez-Sola; Iker Uriarte; María Arechederra; Maite G Fernández-Barrena; Carmen Berasain; Cynthia Ju; Matías A Avila
Journal:  Ann Transl Med       Date:  2018-06

Review 3.  Endocrine Adiponectin-FGF15/19 Axis in Ethanol-Induced Inflammation and Alcoholic Liver Injury.

Authors:  Min You; Zhou Zhou; Michael Daniels; Alvin Jogasuria
Journal:  Gene Expr       Date:  2017-11-02

4.  Soy compared with milk protein in a Western diet changes fecal microbiota and decreases hepatic steatosis in obese OLETF rats.

Authors:  Matthew R Panasevich; Colin M Schuster; Kathryn E Phillips; Grace M Meers; Sree V Chintapalli; Umesh D Wankhade; Kartik Shankar; Dustie N Butteiger; Elaine S Krul; John P Thyfault; R Scott Rector
Journal:  J Nutr Biochem       Date:  2017-05-31       Impact factor: 6.048

Review 5.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

6.  MitoNEET Deficiency Alleviates Experimental Alcoholic Steatohepatitis in Mice by Stimulating Endocrine Adiponectin-Fgf15 Axis.

Authors:  Xudong Hu; Alvin Jogasuria; Jiayou Wang; Chunki Kim; Yoonhee Han; Hong Shen; Jiashin Wu; Min You
Journal:  J Biol Chem       Date:  2016-08-29       Impact factor: 5.157

7.  Changes in the intestinal expression of drug metabolism-related genes in a piglet model of parenteral nutrition.

Authors:  Li-Na Dai; Yu-Ling Zhao; Lu Jiang; Jun-Kai Yan
Journal:  Nutr Metab (Lond)       Date:  2022-03-09       Impact factor: 4.169

Review 8.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 9.  Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ignazio Grattagliano; Agostino Di Ciaula; Jacek Baj; Emilio Molina-Molina; Harshitha Shanmugam; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Methods Mol Biol       Date:  2021

10.  Grape Seed Procyanidins and Cholestyramine Differentially Alter Bile Acid and Cholesterol Homeostatic Gene Expression in Mouse Intestine and Liver.

Authors:  Rebecca M Heidker; Gianella C Caiozzi; Marie-Louise Ricketts
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.